ESR1 and breast cancer: In particular studies by Castellano et al. have shown that AR is expressed in 70.9% of ER positive breast cancers [46] and that the AR/ER ratio ≥2 identifies a subgroup of patients with aggressive biological features and may represent an additional independent marker of worse prognosis [47].